Neurocrine’s Phase III trial of valbenazine for DCP fails to meet endpoints
The principal aim of the study was to determine whether valbenazine could improve chorea in those with DCP.
Services
UAE positions itself as a regional leader and a clinical trial hub
Psyence gains HREC nod to use PsyLabs’ psilocybin in adjustment disorder trial
Altimmune reports positive topline results from IMPACT Phase IIb trial
Soligenix reports Phase IIa SGX945 trial data for Behçet’s disease
Qihan Biotech begins subject dosing in Phase I/IIa study of QT-019B for rSLE
Revealing the human and business cost of clinical trial inefficiencies for Data Managers and CRAs
Hutchmed begins Phase I HMPL-A251 clinical development programme
